Here are 1-3 brief analogies to describe Quantum BioPharma (QNTM):

• An early-stage biotech company, much like a smaller, more specialized Biogen, focused on developing new treatments for neurodegenerative diseases like multiple sclerosis.
• Think of it as a small, discovery-focused pharmaceutical company, similar to a miniature Eli Lilly, but specializing in early-stage drugs for challenging conditions like neurodegenerative disorders and alcohol misuse.

• Lucid-MS: A patented new chemical entity in Phase 2 clinical trials aimed at preventing and reversing myelin degradation for multiple sclerosis.
• Treatment for alcohol misuse: A developing therapeutic solution intended for use in hospitals and medical practices.
• Strategic Investments: A portfolio comprising loans secured by residential property.

Quantum BioPharma Ltd. (QNTM) is a biopharmaceutical company primarily engaged in the research and development of drug candidates. Its lead compound, Lucid-MS, is currently in Phase 2 clinical trials, and other treatments are also under development. Given that the company's primary biopharmaceutical products are still in the clinical development phase and not yet approved for commercial sale, Quantum BioPharma does not currently have major customers for these products.

When its drug candidates are eventually commercialized and approved, customers would typically include institutional buyers such as hospitals, pharmacies, other medical practices, and potentially pharmaceutical distributors or licensing partners.

Zeeshan Saeed, Chief Executive Officer, Co-Founder and Executive Co-Chairman of the Board

Mr. Saeed is a co-founder of Quantum BioPharma, instrumental in securing its initial seed capital and guiding its transition to a publicly traded company. He previously served as President of ZZ Telecommunications Inc., a long-distance telecommunications carrier, and was the founder and CEO of Platinum Telecommunications Inc. He has extensive experience in international capital markets, having assisted numerous startups in raising initial funding and securing listings on various stock exchanges.

Donal Carroll, Chief Financial Officer

Mr. Carroll was appointed Chief Financial Officer effective August 30, 2024. He initially joined the company as interim CFO in 2018, became permanent CFO in December 2019, and served until May 2021. He was then appointed COO on August 15, 2021. Mr. Carroll brings 20 years of corporate finance leadership and public company experience. His prior roles include Accounting Supervisor with Alberto Culver, Controller with Videojet Technologies, and Corporate Controller with Cardinal Meats, where he played a key role in major restructuring activities, mergers and acquisitions, and the implementation of new internal controls and ERP systems.

Dr. Lakshmi P. Kotra, PhD, President Quantum BioPharma, CEO Quantum BioPharma Australia Pty Ltd

Dr. Kotra joined Quantum BioPharma as CEO of its wholly-owned subsidiary, Lucid, following the acquisition of Lucid Psycheceuticals in September 2021. He is a Senior Scientist at Krembil Brain Institute, University Health Network (UHN), and a Professor of Medicinal Chemistry at the University of Toronto. Dr. Kotra is a recipient of the Julia Levy Award (2021) and has authored or co-authored over 130 publications and delivered over 140 scientific talks internationally.

Anthony Durkacz, Co-Founder and Executive Co-Chairman of the Board

Mr. Durkacz is a co-founder of Quantum BioPharma (formerly FSD Pharma) and has also co-founded Ronday. He has served as a director and Executive Vice-President of First Republic Capital Corporation since 2014. Previously, he was President of Capital Ideas Investor Relations and served as Chief Financial Officer and a director of Snipp Interactive Inc., where he was instrumental in its financing and public listing.

Jason Sawyer, Head of Finance and M&A

Mr. Sawyer is an experienced financier who led Access Alternative Group S.A., a Bahamas-based alternative investment and advisory firm, for over 20 years. Under his leadership, AAG and its affiliates facilitated over $5 billion in capital placement, including capital formation and investment in private and public startups, early-stage growth companies, and targeted M&A across various sectors. He also serves on multiple corporate boards and advisory committees.

The key risks to Quantum BioPharma's business, which trades under the symbol QNTM and focuses on biopharmaceutical research and development, are primarily associated with the inherent challenges of drug development and the biopharmaceutical industry itself.

1. Clinical Trial Failure and Regulatory Approval Risk: Quantum BioPharma's lead compound, Lucid-MS, is a patented new chemical entity for multiple sclerosis that has successfully completed Phase 1 clinical trials and is advancing to Phase 2. However, the biopharmaceutical industry faces significant hurdles in clinical development, with Phase 2 often being a major point of attrition. A substantial percentage of drugs that enter Phase 2 fail to progress to Phase 3, often due to insufficient efficacy or safety concerns. The lengthy timelines for drug development, typically 5 to 10 years from preclinical to market, coupled with low overall success rates, mean that the ultimate success and commercialization of Lucid-MS or any other drug candidate are highly uncertain and directly impact the company's future viability.

2. Capital Requirements and Financing Risk: As a biopharmaceutical company with drug candidates in various stages of development and no commercialized products generating revenue, Quantum BioPharma incurs substantial research and development costs. Biotech firms are highly dependent on external funding to finance their R&D projects and ongoing operations, as they typically lack internally generated cash flows like larger pharmaceutical companies. The high burn rate associated with costly clinical trials and specialized staff presents a significant risk, and the company's ability to secure adequate and non-dilutive financing for future clinical trials and potential commercialization is critical. Failure to raise sufficient capital could lead to delays or cessation of development programs.

3. Competition and Intellectual Property Risk: Quantum BioPharma operates in a highly competitive biopharmaceutical market. While Lucid-MS is described as a "patented new chemical entity," maintaining and defending intellectual property (IP) rights is crucial but not without challenges. Competitors may develop alternative or superior treatments for the challenging neurodegenerative, inflammatory, metabolic, and alcohol misuse disorders that Quantum BioPharma targets. Additionally, patents can be challenged or may expire, potentially leading to increased competition from generics or biosimilars in the future and impacting market exclusivity and profitability.

The addressable markets for Quantum BioPharma's main products are substantial, particularly for its lead compound, Lucid-MS, targeting multiple sclerosis, and its treatment for alcohol misuse disorder.

Multiple Sclerosis (MS) Treatment Market

The global multiple sclerosis therapeutic market was estimated at approximately USD 27.39 billion in 2024 and is projected to grow to USD 38.62 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.93% from 2025 to 2030. North America holds the largest share of this global market, with the U.S. dominating the North American segment.

Specifically for the United States, the multiple sclerosis drugs market size was valued at approximately USD 8.44 billion in 2025 and is anticipated to increase to around USD 17.15 billion by 2034, growing at a CAGR of 8.18% from 2025 to 2034.

Alcohol Misuse Disorder (AUD) Treatment Market

Globally, the alcohol use disorder treatment market size was more than USD 1.36 billion in 2025 and is expected to grow to USD 2.46 billion by 2035, with a CAGR of over 6.1%. North America is projected to be the largest region in this market by 2035, holding around a 46% share.

In the United States, the Alcohol Use Disorder Market size was approximately USD 1.106 billion in 2025 and is projected to increase during the forecast period up to 2034.

Quantum BioPharma Ltd. (QNTM) is anticipated to experience future revenue growth over the next 2-3 years primarily through the commercialization and advancement of its specialized product portfolio and related licensing agreements. The company's strategy focuses on monetizing its innovative biotech solutions, particularly within the neurodegenerative, inflammatory, metabolic, and alcohol misuse disorder sectors.

Three expected drivers of Quantum BioPharma's revenue growth include:

1. Royalties from the Commercialization of unbuzzd™: Quantum BioPharma has licensed its alcohol detoxification technology for recreational use to Celly Nutrition (rebranded as Unbuzzd Wellness Inc.), which launched the unbuzzd™ product on Amazon in August 2024. Quantum BioPharma is entitled to a 7% royalty on unbuzzd™ sales until cumulative payments reach $250 million, after which the royalty rate will be 3% in perpetuity. This licensing agreement provides a direct and active revenue stream expected to grow as the product gains market traction in the expanding global hangover remedy market.

2. Commercialization of Qlarity: Health Canada approved Quantum BioPharma's natural health product, Qlarity, for sale in Canada as of November 2025. This regulatory approval enables the company to bring a new product to market, establishing an additional revenue stream within the Canadian health product sector.

3. Advancement and Potential Partnerships for rekvry: Quantum BioPharma has initiated the development of rekvry, an alcohol misuse treatment designed for emergency and hospital settings. The company's management has identified this as a "near-term monetization event," indicating the potential for revenue generation within the next 2-3 years. While direct product sales may not occur within this timeframe, potential revenue growth could arise from strategic partnerships, licensing agreements, or milestone payments as the formulation development progresses and clinical trials advance.

Share Repurchases

• Quantum BioPharma, under its former name FSD Pharma Inc., completed the repurchase of 1,904,700 shares for $4 million under a buyback program announced in January 2023.
• In January 2023, the Board of Directors authorized a normal course issuer bid to repurchase up to 1,925,210 Subordinate Class B Voting Shares, representing approximately 5% of its issued and outstanding shares.
• Prior to the January 2023 program, the company repurchased for cancellation 1,999,800 Subordinate Voting Shares at an average price of approximately $1.20 CDN per share through a normal course issuer bid that expired in December 2022.

Share Issuance

• Quantum BioPharma closed multiple tranches of financing totaling $2.5 million USD for the year ended December 31, 2024.
• In February 2024, the company settled $637,650 in debt by issuing 545,000 Class B Subordinate Voting shares at a deemed price of $1.17 per share.
• A non-brokered private placement offering of up to 4,000 convertible debenture units, each priced at $1,000 (totaling up to $4 million), was planned for March 2026, with proceeds intended for business development and general working capital.

Inbound Investments

• Quantum BioPharma completed multiple tranches of financing for $2.5 million USD during the year ended December 31, 2024.
• The company received approximately CAD 0.00075 million in funding from Xorax Family Trust and Fortius Research and Trading Corporation around December 2024.
• A planned non-brokered private placement offering in March 2026 aims to raise up to $4 million through convertible debenture units.

Outbound Investments

• FSD Pharma Inc. (now Quantum BioPharma) acquired Lucid Psycheceuticals in September 2021 for $8.82 million.
• The company purchased $3.5 million worth of Bitcoin and other cryptocurrencies to diversify its Treasury as of December 31, 2024.
• Quantum BioPharma spun out the OTC version of its unbuzzd™ product to Celly Nutrition Corp., retaining 25.71% ownership as of June 30, 2024, and securing royalty payments of 7% of sales until $250 million is reached, then 3% in perpetuity.

Capital Expenditures

• For the year ended December 31, 2024, external research and development fees, a significant allocation for advancing clinical assets, increased to $6.1 million USD from $3.9 million USD in 2023.
• As of June 30, 2024, the company recorded $21,918 in cash used for the purchase of investments under investing activities.
• Depreciation and amortization, indicative of asset usage, was $256,954 for the six months ended June 30, 2024, and $2,237,289 for the year ended December 31, 2023.